Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan

D. Dunbar Ivy; Aimee Doran; Lori Claussen; Deborah Bingaman; Anji Yetman

doi:10.1016/j.amjcard.2003.12.031

Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan

D. Dunbar Ivy, Aimee Doran, Lori Claussen, Deborah Bingaman, Anji Yetman

Research output: Contribution to journal › Article › peer-review

80 Scopus citations

Abstract

In 7 of 8 children with idiopathic pulmonary arterial hypertension treated with intravenous epoprostenol for >1 year, concomitant use of bosentan allowed a reduction of epoprostenol and decreased its associated side effects without deterioration of clinical and hemodynamic parameters. In 3 children with normal or near-normal pulmonary artery pressure on epoprostenol, the addition of bosentan allowed discontinuation of epoprostenol and stabilization of hemodynamics for up to 1 year.

Original language	English (US)
Pages (from-to)	943-946
Number of pages	4
Journal	American Journal of Cardiology
Volume	93
Issue number	7
DOIs	https://doi.org/10.1016/j.amjcard.2003.12.031
State	Published - Apr 1 2004
Externally published	Yes

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.amjcard.2003.12.031

Cite this

@article{554ee9e281c4401dba2d1a462fcc9cee,

title = "Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan",

abstract = "In 7 of 8 children with idiopathic pulmonary arterial hypertension treated with intravenous epoprostenol for >1 year, concomitant use of bosentan allowed a reduction of epoprostenol and decreased its associated side effects without deterioration of clinical and hemodynamic parameters. In 3 children with normal or near-normal pulmonary artery pressure on epoprostenol, the addition of bosentan allowed discontinuation of epoprostenol and stabilization of hemodynamics for up to 1 year.",

author = "Ivy, {D. Dunbar} and Aimee Doran and Lori Claussen and Deborah Bingaman and Anji Yetman",

note = "Funding Information: This research was supported by grant MO1 RR00069 from the General Clinical Research Centers Program, National Center for Research Resources, National Institutes of Health, Bethesda, Maryland. ",

year = "2004",

month = apr,

day = "1",

doi = "10.1016/j.amjcard.2003.12.031",

language = "English (US)",

volume = "93",

pages = "943--946",

journal = "American Journal of Cardiology",

issn = "0002-9149",

publisher = "Elsevier Inc.",

number = "7",

}

TY - JOUR

T1 - Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan

AU - Ivy, D. Dunbar

AU - Doran, Aimee

AU - Claussen, Lori

AU - Bingaman, Deborah

AU - Yetman, Anji

N1 - Funding Information: This research was supported by grant MO1 RR00069 from the General Clinical Research Centers Program, National Center for Research Resources, National Institutes of Health, Bethesda, Maryland.

PY - 2004/4/1

Y1 - 2004/4/1

N2 - In 7 of 8 children with idiopathic pulmonary arterial hypertension treated with intravenous epoprostenol for >1 year, concomitant use of bosentan allowed a reduction of epoprostenol and decreased its associated side effects without deterioration of clinical and hemodynamic parameters. In 3 children with normal or near-normal pulmonary artery pressure on epoprostenol, the addition of bosentan allowed discontinuation of epoprostenol and stabilization of hemodynamics for up to 1 year.

AB - In 7 of 8 children with idiopathic pulmonary arterial hypertension treated with intravenous epoprostenol for >1 year, concomitant use of bosentan allowed a reduction of epoprostenol and decreased its associated side effects without deterioration of clinical and hemodynamic parameters. In 3 children with normal or near-normal pulmonary artery pressure on epoprostenol, the addition of bosentan allowed discontinuation of epoprostenol and stabilization of hemodynamics for up to 1 year.

UR - http://www.scopus.com/inward/record.url?scp=1842476943&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842476943&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2003.12.031

DO - 10.1016/j.amjcard.2003.12.031

M3 - Article

C2 - 15050507

AN - SCOPUS:1842476943

SN - 0002-9149

VL - 93

SP - 943

EP - 946

JO - American Journal of Cardiology

JF - American Journal of Cardiology

IS - 7

ER -

Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this